Proxima: $80 Million Raised To Power The Next Generation Of Proximity-Based Medicines
By Amit Chowdhry ● Jan 13, 2026
Proxima, the AI-native biotech company developing drug discovery tools and therapeutics for proximity-based medicines, has raised an oversubscribed $80 million seed round and rebranded from VantAI as it sharpens its focus on proximity therapeutics. The financing was led by DCVC, with participation from NVentures (NVIDIA’s venture capital arm), Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, Modi Ventures, and other strategic and institutional backers. As part of the round, DCVC General Partner Jason Pontin will join Proxima’s board.